Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Ocular Therapeutix, Inc.
What AI says about Ocular Therapeutix, Inc.
Ocular Therapeutix is dedicated to redefining the treatment experience for retinal diseases, focusing on innovative therapies like AXPAXLI™ for conditions such as wet AMD. Their mission is to reduce the burden of treatment on patients and caregivers while preserving vision for the long term.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
AXPAXLI™
An investigational axitinib hydrogel administered by intravitreal injection, currently in Phase 3 clinical trials for wet age-related macular degeneration.
Dextenza
Innovative eye care solutions aimed at addressing unmet needs in eye care.
Common Questions
What is AXPAXLI™?
AXPAXLI™ is an investigational axitinib hydrogel designed for intravitreal injection, currently undergoing Phase 3 clinical trials for treating wet age-related macular degeneration.
What conditions does Ocular Therapeutix focus on?
Ocular Therapeutix primarily focuses on retinal diseases, including wet age-related macular degeneration (AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
How does Ocular Therapeutix aim to reduce treatment burden?
Ocular Therapeutix aims to reduce the therapeutic burden by developing innovative treatments that minimize the need for frequent injections and improve patient adherence.